Published in Respir Med on June 24, 2008
Genome-wide association study of short-acting β2-agonists. A novel genome-wide significant locus on chromosome 2 near ASB3. Am J Respir Crit Care Med (2015) 1.42
Rapid effects of estrogen on intracellular Ca2+ regulation in human airway smooth muscle. Am J Physiol Lung Cell Mol Physiol (2010) 1.08
Brain-derived neurotrophic factor induces proliferation of human airway smooth muscle cells. J Cell Mol Med (2012) 1.05
A fungal protease allergen provokes airway hyper-responsiveness in asthma. Nat Commun (2015) 0.94
Mitochondria in lung diseases. Expert Rev Respir Med (2013) 0.93
Update on anticytokine treatment for asthma. Biomed Res Int (2013) 0.92
Large-scale profiling of signalling pathways reveals an asthma specific signature in bronchial smooth muscle cells. Oncotarget (2016) 0.83
Alteration of airway responsiveness mediated by receptors in ovalbumin-induced asthmatic E3 rats. Acta Pharmacol Sin (2009) 0.80
Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD. Ther Clin Risk Manag (2015) 0.79
MAG-EPA and 17,18-EpETE target cytoplasmic signalling pathways to reduce short-term airway hyperresponsiveness. Pflugers Arch (2014) 0.79
Pathophysiology of bronchoconstriction: role of oxidatively damaged DNA repair. Curr Opin Allergy Clin Immunol (2016) 0.78
Interdicting Gq Activation in Airway Disease by Receptor-Dependent and Receptor-Independent Mechanisms. Mol Pharmacol (2015) 0.78
Aberrant DNA Methylation of Phosphodiestarase 4D Alters Airway Smooth Muscle Cell Phenotypes. Am J Respir Cell Mol Biol (2016) 0.76
Hemangiomas of the maxillofacial area: Case Report, Classification and Treatment Planning. Open Med (Wars) (2015) 0.75
Cushing's like syndrome in typical bronchial carcinoid a case report and review of the literature. Int J Surg Case Rep (2016) 0.75
Pharmacologic rationale, efficacy and safety of the fixed-dose co-formulation of indacaterol and glycopyrronium. Multidiscip Respir Med (2014) 0.75
Suppression of the increasing level of acetylcholine-stimulated intracellular Ca(2+) in guinea pig airway smooth muscle cells by mabuterol. Biomed Rep (2015) 0.75
Role of FDG-PET scan in staging of pulmonary epithelioid hemangioendothelioma. Open Med (Wars) (2016) 0.75
Compartmentalized cAMP Responses to Prostaglandin EP2 Receptor Activation in Human Airway Smooth Muscle Cells. Br J Pharmacol (2017) 0.75
Airway smooth muscle dysfunction in Pompe (Gaa-/-) mice. Am J Physiol Lung Cell Mol Physiol (2017) 0.75
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med (2013) 9.65
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol (2007) 7.34
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol (2005) 6.06
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med (2013) 5.72
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood (2011) 4.43
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood (2013) 3.78
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med (2004) 3.26
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica (2011) 3.11
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood (2013) 2.97
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica (2008) 2.92
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica (2008) 2.69
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood (2012) 2.32
Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood (2006) 2.29
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica (2010) 2.14
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood (2007) 2.10
Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J (2005) 1.95
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica (2002) 1.91
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol (2008) 1.90
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol (2013) 1.88
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood (2014) 1.87
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood (2013) 1.84
Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes. Br J Haematol (2008) 1.83
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood (2009) 1.80
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol (2008) 1.68
Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br J Haematol (2007) 1.64
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood (2011) 1.63
Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respir Med (2011) 1.61
Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood (2004) 1.59
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood (2011) 1.56
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica (2008) 1.54
The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS One (2008) 1.52
The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thromb Haemost (2005) 1.49
Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis. J Res Med Sci (2012) 1.47
Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors. Leuk Lymphoma (2013) 1.47
Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood (2005) 1.44
HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia. Leuk Lymphoma (2007) 1.43
Monoclonal gammopathy of undetermined significance: a new proposal of workup. Eur J Haematol (2013) 1.42
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol (2007) 1.42
[Hyperferritinemia-cataract syndrome associated to the HFE gene mutation. Two new Spanish families and a new mutation (A37T: "Zaragoza")]. Med Clin (Barc) (2006) 1.42
Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma. Leuk Lymphoma (2011) 1.40
Ring sideroblasts and sideroblastic anemias. Haematologica (2011) 1.37
p53 lesions in leukemic transformation. N Engl J Med (2011) 1.34
Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther (2005) 1.33
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood (2013) 1.32
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood (2005) 1.31
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood (2013) 1.30
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood (2014) 1.30
Mitochondrial ferritin: a new player in iron metabolism. Blood Cells Mol Dis (2003) 1.29
Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica (2006) 1.29
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica (2011) 1.25
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood (2010) 1.23
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer (2014) 1.22
Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Haematologica (2011) 1.21
Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia. Am J Hematol (2006) 1.20
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood (2014) 1.19
Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J (2012) 1.18
Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica (2012) 1.17
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer (2006) 1.17
Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome. Blood (2010) 1.17
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood (2011) 1.16
Somatic deletion of the normal beta-globin gene leading to thalassaemia intermedia in heterozygous beta-thalassaemic patients. Br J Haematol (2004) 1.15
Molecular basis of myelodysplastic/myeloproliferative neoplasms. Haematologica (2009) 1.14
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood (2008) 1.13
The potential of biologics for the treatment of asthma. Nat Rev Drug Discov (2012) 1.11
TP53 codon 72 polymorphism in patients with chronic myeloid leukemia. Haematologica (2004) 1.09
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood (2013) 1.09
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am J Hematol (2011) 1.09
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica (2010) 1.08
Bone marrow assessment in asymptomatic immunoglobulin M monoclonal gammopathies. Br J Haematol (2014) 1.08
The role of JAK2 mutations in RARS and other MDS. Hematology Am Soc Hematol Educ Program (2008) 1.07
Natural history of juvenile haemochromatosis. Br J Haematol (2002) 1.07
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. Am J Hematol (2012) 1.07
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood (2007) 1.07
TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. Pulm Pharmacol Ther (2009) 1.07
Genetic and clinical heterogeneity of ferroportin disease. Br J Haematol (2005) 1.07
Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol (2005) 1.07
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. Ann Hematol (2004) 1.06
Epidemiological survey on incidence and treatment of community acquired pneumonia in Italy. Respir Med (2005) 1.06
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood (2014) 1.06
Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir Res (2006) 1.04
Mitogen-activated protein kinases and asthma. J Cell Physiol (2005) 1.04
Evidence of angiogenesis in bronchial biopsies of smokers with and without airway obstruction. Respir Med (2006) 1.00